The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Kwee Yong, Paul McGarry et al.|BMC Hematology|2016Cited by 9
Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior RegimenKwee Yong, Catherine Williams, Sarah Brown et al.|Blood|2015Cited by 6